Regen BioPharma, Inc.
RGBP
$0.00
$0.000.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -281.23% | 5,212.89% | -87.80% | -111.49% | -28.59% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 218.92% | -30.95% | -29.37% | 181.43% | -272.09% |
| Total Other Non-Cash Items | 257.35% | -800.16% | 85.38% | 63.85% | 7,123.08% |
| Change in Net Operating Assets | 4.34% | 183.14% | -231.13% | 159.35% | -39.88% |
| Cash from Operations | 56.96% | 37.55% | -198.04% | 22.82% | 67.56% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -41.07% | -- | -- | 54.32% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 106.38% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -57.14% | -42.76% | 102.13% | 55.81% | -64.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -368.75% | -10,733.33% | 210.97% | 100.00% |